Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Pronorvistaon Apr 18, 2023 2:14pm
266 Views
Post# 35401161

Antibe

Antibe

About Yung Wu

Yung Wu has been CEO of the MaRS Discovery District since November 2017.

As a serial entrepreneur and investor, Yung has built breakthrough scale-stage companies in enterprise software, mobile analytics and big data, media and entertainment, technology services and biotech. He is a co-founder of two not-for-profit organizations, the Coalition of Innovation Leaders Against Racism (CILAR) and DifferentIsCool (DiSC). He currently serves on the boards of OMERS, the Toronto Region Board of Trade, Antibe Therapeutics Inc. (TSX: ATE) and is a member of Green Shield Canada. He is a Governor in Council appointee to Canada’s Net-Zero Advisory Body.

He has been recognized as one of Canada’s “Top 40 under 40” and for leading one of Canada’s “50 Best Managed Private Companies” in the nation. Wu has a B.Sc. Computer Science, Economics and Mathematics from the University of Toronto and is a graduate of the Entrepreneurial Master’s Program at the Massachusetts Institute of Technology, the NACD Cybersecurity Oversight Certification Program at Carnegie Mellon University, a member of MENSA, the Young Presidents Organization (YPO) and the Institute of Corporate Directors (ICD.D).

<< Previous
Bullboard Posts
Next >>